Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131, Padova, Italy.
Sci Rep. 2020 Dec 1;10(1):20927. doi: 10.1038/s41598-020-77700-z.
Coronavirus SARS-CoV-2 is a recently discovered single-stranded RNA betacoronavirus, responsible for a severe respiratory disease known as coronavirus disease 2019, which is rapidly spreading. Chinese health authorities, as a response to the lack of an effective therapeutic strategy, started to investigate the use of lopinavir and ritonavir, previously optimized for the treatment and prevention of HIV/AIDS viral infection. Despite the clinical use of these two drugs, no information regarding their possible mechanism of action at the molecular level is still known for SARS-CoV-2. Very recently, the crystallographic structure of the SARS-CoV-2 main protease (M), also known as C30 Endopeptidase, was published. Starting from this essential structural information, in the present work we have exploited supervised molecular dynamics, an emerging computational technique that allows investigating at an atomic level the recognition process of a ligand from its unbound to the final bound state. In this research, we provided molecular insight on the whole recognition pathway of Lopinavir, Ritonavir, and Nelfinavir, three potential C30 Endopeptidase inhibitors, with the last one taken into consideration due to the promising in-vitro activity shown against the structurally related SARS-CoV protease.
新型冠状病毒 SARS-CoV-2 是一种新发现的单链 RNA β 冠状病毒,可引发严重的呼吸道疾病,即 2019 年冠状病毒病,该病毒传播迅速。中国卫生部门针对缺乏有效治疗策略的情况,开始研究洛匹那韦和利托那韦的应用,这两种药物先前已优化用于治疗和预防艾滋病毒/艾滋病病毒感染。尽管这两种药物已在临床上使用,但对于 SARS-CoV-2,仍不清楚其在分子水平上可能的作用机制。最近,新型冠状病毒主蛋白酶(M)的晶体结构,也称为 C30 内切酶,已被公布。基于这一关键的结构信息,在目前的工作中,我们利用了有监督的分子动力学,这是一种新兴的计算技术,可以在原子水平上研究配体从不结合状态到最终结合状态的识别过程。在这项研究中,我们提供了洛匹那韦、利托那韦和奈非那韦的分子识别途径的分子见解,这三种都是潜在的 C30 内切酶抑制剂,最后一种被考虑在内是因为它对结构上相关的 SARS-CoV 蛋白酶显示出有前景的体外活性。